dr. S.J. Vastert

dr. S.J. Vastert

Associate Professor - medical
dr. S.J. Vastert
  • Center for Translational Immunology (CTI) Research
  • Rheumatology Research 1
  • Immunology

Research Programs

Child Health



Bas is a pediatric rheumatologist in the “EULAR center of excellence in rheumatology" Wilhelmina Children’s Hospital Utrecht. Besides being an esteemed clinician in the field of Pediatric Rheumatology, he has developed into a translational researcher, with a PhD on mechanisms of disease and therapy in severe JIA in 2013. From 2015, he has been starting a translational research group together with Jorg van Loosdregt, molecular biologist. They currently supervise 5 PhD students, 1 post-doc and 2 technicians together, within the Center of Translational Immunology in Utrecht (v Loosdregt-Vastert group). Their labgroup aims to translate cutting edge science into clinical benefit for patients and their research focusses on systemic JIA and on development of novel treatment strategies for JIA. Bas is currently leading a multi-center prospective trial implementing a biomarker driven stop-strategy for rIL-1RA therapy in systemic JIA in the Netherlands (the ESTIS trial).

In addition, as a designated Young Investigator, Bas is the Dutch lead for all translational laboratory studies within UCAN CAN DU (major infrastructural research project 2017-2021 in Canada and the Netherlands).

Key words: Translational research in childhood arthritis, biology of systemic JIA, (regulation of) auto-inflammation, regulation of autoimmune inflammation, epigenetics.

Side Activities

  • member editoreal board van Pediatric Rheumatology Online Journal
  • associate editor Rheumatology

Fellowship and Awards

- 2007: Young investigator Meeting, Pediatric rheumatology European Society: Award for best basic abstract .

- 2014: Wilhelmina Research Fund (co-applicant), € 150 000 : Dissecting the complex role of S100-proteins in systemic juvenile idiopathic arthritis.

- 2015: ZonMW Rational Pharmacotherapy grant, € 340 000 : Biomarker guided treatment and stop strategy for rIL-1RA therapy in systemic JIA.

- 2016-2019: Wilhelmina Kinderziekenhuis Fonds, Rosenberg foundation / Vrienden WKZ (€340 000): Modulation of Treg in JIA by Nicotinamide. Principal Investigator, no overlap.

- 2016-2021: ZonMW grant, Rational Pharmacotherapy for implementation of biomarker guided tapering strategy of rIL-1RA in systemic JIA (€340 000 + €190 000 contribution Sobi). Principal Investigator, clinical trial, no overlap.

- 2017-2021: UCAN CAN DU: (8,0 mln Can$). Canada – Netherlands Personalized Medicine Network in Childhood Arthritis and Rheumatic diseases. Young Investigator, NL lead for laboratory studies within UCAN CAN DU. (PI: R. Yeung, NM Wulffraat, co-PI JF Swart, S. Benseler).   


Research Output (137)

Factors associated with care- and health-related quality of life of caregivers of children with juvenile idiopathic arthritis

Grazziotin Luiza R., Currie Gillian, Twilt Marinka, IJzerman Maarten J., Kip Michelle M.A., Koffijberg Hendrik, Bonsel Gouke, Benseler Susanne M., Swart Joost F., Vastert Sebastiaan J., Wulffraat Nico M., Yeung Rae S.M., Armbrust Wineke, van den Berg J. Merlijn, Marshall Deborah A. 23 Jul 2022, In: Pediatric rheumatology online journal. 20 , p. 1-12

Real-world data reveals the complexity of disease modifying anti-rheumatic drug treatment patterns in juvenile idiopathic arthritis:an observational study

Grazziotin Luiza R., Currie Gillian, Twilt Marinka, Ijzerman Maarten J., Kip Michelle M.A., Koffijberg Hendrik, Benseler Susanne M., Swart Joost F., Vastert Sebastiaan J., Wulffraat Nico M., Yeung Rae S.M., Marshall Deborah A. 11 Apr 2022, In: Pediatric rheumatology online journal. 20 , p. 1-11

Anakinra in Patients With Systemic Juvenile Idiopathic Arthritis:Long-term Safety From the Pharmachild Registry

Giancane Gabriella, Papa Riccardo, Vastert Sebastiaan, Bagnasco Francesca, Swart Joost F., Quartier Pierre, Antón Jordi, Kamphuis Sylvia, Sanner Helga, Glerup Mia, De Benedetti Fabrizio, Tsitsami Elena, Remesal Agustin, Moreno Estefania, De Inocencio Jaime, Myrup Charlotte, Pallotti Chiara, Koné-Paut Isabelle, Franck-Larsson Karin, Malmström Håkan, Cederholm Susanna, Pistorio Angela, Wulffraat Nico, Ruperto Nicolino, 1 Feb 2022, In: Journal of Rheumatology. 49 , p. 398-407 10 p.

Conserved human effector Treg cell transcriptomic and epigenetic signature in arthritic joint inflammation

Mijnheer Gerdien, Lutter Lisanne, Mokry Michal, van der Wal Marlot, Scholman Rianne, Fleskens Veerle, Pandit Aridaman, Tao Weiyang, Wekking Mark, Vervoort Stephin, Roberts Ceri, Petrelli Alessandra, Peeters Janneke G C, Knijff Marthe, de Roock Sytze, Vastert Sebastiaan, Taams Leonie S, van Loosdregt Jorg, van Wijk Femke Dec 2021, In: Nature Communications. 12 , p. 1-16

Genomic Health Literacy Interventions in Pediatrics:Scoping Review

Gupta Aarushi, Cafazzo Joseph A., IJzerman Maarten J., Swart Joost F., Vastert Sebastiaan, Wulffraat Nico M., Benseler Susanne, Marshall Deborah, Yeung Rae, Twilt Marinka Dec 2021, In: Journal of Medical Internet Research. 23

Pathogenesis and Treatment of Refractory Disease Courses in Systemic Juvenile Idiopathic Arthritis:Refractory Arthritis, Recurrent Macrophage Activation Syndrome and Chronic Lung Disease

Erkens Remco, Esteban Ysabella, Towe Christopher, Schulert Grant, Vastert Sebastiaan Nov 2021, In: Rheumatic Disease Clinics of North America. 47 , p. 585-606 22 p.

Immunometabolic factors in adolescent chronic disease are associated with Th1 skewing of invariant Natural Killer T cells

Ververs Francesca, Engelen Suzanne, Nuboer Roos, Vastert SJ, van der Ent Kors , van 't Land Belinda, Garssen Johan, Monaco Claudia, Boes Marianne, Schipper Henk 11 Oct 2021, In: Scientific Reports. 11 11 p.

Long-term efficacy and safety of canakinumab in patients with mevalonate kinase deficiency:results from the randomised Phase 3 CLUSTER trial

Jeyaratnam Jerold, Simon Anna, Calvo Inmaculada, Constantin Tamas, Shcherbina Anna, Hofer Michael, Gattorno Marco, Martini Alberto, Bader-Meunier Brigitte, Vastert Bas, Levy Jeremy, Dekker Elise, de Benedetti Fabrizio, Frenkel Joost 23 Sep 2021, In: Rheumatology (Oxford, England). 61 , p. 2088-2094 7 p.

Evaluation of Real-World Healthcare Resource Utilization and Associated Costs in Children with Juvenile Idiopathic Arthritis:A Canadian Retrospective Cohort Study

Grazziotin Luiza R., Currie Gillian, Twilt Marinka, Ijzerman Maarten J., Kip Michelle M.A., Koffijberg Hendrik, Benseler Susanne M., Swart Joost F., Vastert Sebastiaan J., Wulffraat Nico M., Yeung Rae S.M., Johnson Nicole, Luca Nadia J., Miettunen Paivi M., Schmeling Heinrike, Marshall Deborah A., Sep 2021, In: Rheumatology and therapy. 8 , p. 1303-1322 20 p.

Siglec-1 expression on monocytes is associated with the interferon signature in juvenile dermatomyositis and can predict treatment response

Lerkvaleekul Butsabong, Veldkamp Saskia R, van der Wal Maria M, Schatorjé Ellen J H, Kamphuis Sylvia S M, van den Berg J Merlijn, Muller Petra C E Hissink, Armbrust Wineke, Vastert Sebastiaan J, Wienke Judith, Jansen Marc H A, van Royen-Kerkhof Annet, van Wijk Femke 13 Aug 2021, In: Rheumatology (Oxford, England). 61 , p. 2144-2155 12 p.

All research output

Thank you for your review!

Has this information helped you?

Please tell us why, so that we can improve our website.

Working at UMC Utrecht





Practical maakt gebruik van cookies

Deze website maakt gebruik van cookies Deze website toont video’s van o.a. YouTube. Dergelijke partijen plaatsen cookies (third party cookies). Als u deze cookies niet wilt kunt u dat hier aangeven. Wij plaatsen zelf ook cookies om onze site te verbeteren.

Lees meer over het cookiebeleid

Akkoord Nee, liever niet